Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): A benchmark for emerging targeted cancer therapies

Arie S. Belldegrun, Tobias Klatte, Brian Shuch, Jeffrey C. LaRochelle, David C. Miller, Jonathan W. Said, Stephen B. Riggs, Nazy Zomorodian, Fairooz F. Kabbinavar, Jean B. DeKernion, Allan J. Pantuck

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

BACKGROUND. The management of renal cell carcinoma (RCC) is evolving toward less extirpative surgery and the use of targeted therapy. The authors set out to provide a benchmark against which emerging therapies should be measured. METHODS. A prospective database including clinical and pathological variables for 1632 patients with RCC treated between 1989 and 2005 was queried. Patients were stratified using the University of California-Los Angeles Integrated Staging System (UISS) into low-, intermediate-, and high-risk groups. Disease-specific survival (DSS) was measured. Response to systemic therapy for patients with advanced disease was assessed. RESULTS. Nephrectomy was performed in 1492 patients. Overall 5-, 10-, and 15-year DSS was 55%, 40%, and 29%. For localized disease, 5- and 10-year DSS for UISS low-, intermediate-, and high-risk groups was 97% and 92%, 81% and 61%, and 62% and 41%, respectively. For metastatic disease, 5- and 10-year DSS for UISS low-, intermediate-, and high-risk groups was 41% and 31%, 18% and 7%, and 8% and 0%, respectively. Patients with metastatic disease receiving immunotherapy (n = 453) had complete response in 7% (median survival [MS], 1201 months), partial response in 15% (MS, 42.8 months), stable disease in 33% (MS, 38.6 months), and progressive disease in 45% (MS, 11.6 months). CONCLUSIONS. Most patients with localized RCC do well with surgery alone, but effective adjuvant therapy is needed for patients identified as at high risk for recurrence. For advanced disease, newer targeted and potentially less toxic treatments should be at least as effective as those achieved with aggressive surgical resection and immunotherapy.

Original languageEnglish (US)
Pages (from-to)2457-2463
Number of pages7
JournalCancer
Volume113
Issue number9
DOIs
StatePublished - Nov 1 2008
Externally publishedYes

Fingerprint

Benchmarking
Kidney Neoplasms
Cytokines
Survival
Neoplasms
Renal Cell Carcinoma
Therapeutics
Immunotherapy
Los Angeles
Poisons
Nephrectomy
Databases

Keywords

  • Immunotherapy
  • Interleukin-2
  • Kidney cancer
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Belldegrun, A. S., Klatte, T., Shuch, B., LaRochelle, J. C., Miller, D. C., Said, J. W., ... Pantuck, A. J. (2008). Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): A benchmark for emerging targeted cancer therapies. Cancer, 113(9), 2457-2463. https://doi.org/10.1002/cncr.23851

Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005) : A benchmark for emerging targeted cancer therapies. / Belldegrun, Arie S.; Klatte, Tobias; Shuch, Brian; LaRochelle, Jeffrey C.; Miller, David C.; Said, Jonathan W.; Riggs, Stephen B.; Zomorodian, Nazy; Kabbinavar, Fairooz F.; DeKernion, Jean B.; Pantuck, Allan J.

In: Cancer, Vol. 113, No. 9, 01.11.2008, p. 2457-2463.

Research output: Contribution to journalArticle

Belldegrun, AS, Klatte, T, Shuch, B, LaRochelle, JC, Miller, DC, Said, JW, Riggs, SB, Zomorodian, N, Kabbinavar, FF, DeKernion, JB & Pantuck, AJ 2008, 'Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): A benchmark for emerging targeted cancer therapies', Cancer, vol. 113, no. 9, pp. 2457-2463. https://doi.org/10.1002/cncr.23851
Belldegrun, Arie S. ; Klatte, Tobias ; Shuch, Brian ; LaRochelle, Jeffrey C. ; Miller, David C. ; Said, Jonathan W. ; Riggs, Stephen B. ; Zomorodian, Nazy ; Kabbinavar, Fairooz F. ; DeKernion, Jean B. ; Pantuck, Allan J. / Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005) : A benchmark for emerging targeted cancer therapies. In: Cancer. 2008 ; Vol. 113, No. 9. pp. 2457-2463.
@article{e7c513e5dbfc49e9b281223c4a250bdf,
title = "Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): A benchmark for emerging targeted cancer therapies",
abstract = "BACKGROUND. The management of renal cell carcinoma (RCC) is evolving toward less extirpative surgery and the use of targeted therapy. The authors set out to provide a benchmark against which emerging therapies should be measured. METHODS. A prospective database including clinical and pathological variables for 1632 patients with RCC treated between 1989 and 2005 was queried. Patients were stratified using the University of California-Los Angeles Integrated Staging System (UISS) into low-, intermediate-, and high-risk groups. Disease-specific survival (DSS) was measured. Response to systemic therapy for patients with advanced disease was assessed. RESULTS. Nephrectomy was performed in 1492 patients. Overall 5-, 10-, and 15-year DSS was 55{\%}, 40{\%}, and 29{\%}. For localized disease, 5- and 10-year DSS for UISS low-, intermediate-, and high-risk groups was 97{\%} and 92{\%}, 81{\%} and 61{\%}, and 62{\%} and 41{\%}, respectively. For metastatic disease, 5- and 10-year DSS for UISS low-, intermediate-, and high-risk groups was 41{\%} and 31{\%}, 18{\%} and 7{\%}, and 8{\%} and 0{\%}, respectively. Patients with metastatic disease receiving immunotherapy (n = 453) had complete response in 7{\%} (median survival [MS], 1201 months), partial response in 15{\%} (MS, 42.8 months), stable disease in 33{\%} (MS, 38.6 months), and progressive disease in 45{\%} (MS, 11.6 months). CONCLUSIONS. Most patients with localized RCC do well with surgery alone, but effective adjuvant therapy is needed for patients identified as at high risk for recurrence. For advanced disease, newer targeted and potentially less toxic treatments should be at least as effective as those achieved with aggressive surgical resection and immunotherapy.",
keywords = "Immunotherapy, Interleukin-2, Kidney cancer, Survival",
author = "Belldegrun, {Arie S.} and Tobias Klatte and Brian Shuch and LaRochelle, {Jeffrey C.} and Miller, {David C.} and Said, {Jonathan W.} and Riggs, {Stephen B.} and Nazy Zomorodian and Kabbinavar, {Fairooz F.} and DeKernion, {Jean B.} and Pantuck, {Allan J.}",
year = "2008",
month = "11",
day = "1",
doi = "10.1002/cncr.23851",
language = "English (US)",
volume = "113",
pages = "2457--2463",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005)

T2 - A benchmark for emerging targeted cancer therapies

AU - Belldegrun, Arie S.

AU - Klatte, Tobias

AU - Shuch, Brian

AU - LaRochelle, Jeffrey C.

AU - Miller, David C.

AU - Said, Jonathan W.

AU - Riggs, Stephen B.

AU - Zomorodian, Nazy

AU - Kabbinavar, Fairooz F.

AU - DeKernion, Jean B.

AU - Pantuck, Allan J.

PY - 2008/11/1

Y1 - 2008/11/1

N2 - BACKGROUND. The management of renal cell carcinoma (RCC) is evolving toward less extirpative surgery and the use of targeted therapy. The authors set out to provide a benchmark against which emerging therapies should be measured. METHODS. A prospective database including clinical and pathological variables for 1632 patients with RCC treated between 1989 and 2005 was queried. Patients were stratified using the University of California-Los Angeles Integrated Staging System (UISS) into low-, intermediate-, and high-risk groups. Disease-specific survival (DSS) was measured. Response to systemic therapy for patients with advanced disease was assessed. RESULTS. Nephrectomy was performed in 1492 patients. Overall 5-, 10-, and 15-year DSS was 55%, 40%, and 29%. For localized disease, 5- and 10-year DSS for UISS low-, intermediate-, and high-risk groups was 97% and 92%, 81% and 61%, and 62% and 41%, respectively. For metastatic disease, 5- and 10-year DSS for UISS low-, intermediate-, and high-risk groups was 41% and 31%, 18% and 7%, and 8% and 0%, respectively. Patients with metastatic disease receiving immunotherapy (n = 453) had complete response in 7% (median survival [MS], 1201 months), partial response in 15% (MS, 42.8 months), stable disease in 33% (MS, 38.6 months), and progressive disease in 45% (MS, 11.6 months). CONCLUSIONS. Most patients with localized RCC do well with surgery alone, but effective adjuvant therapy is needed for patients identified as at high risk for recurrence. For advanced disease, newer targeted and potentially less toxic treatments should be at least as effective as those achieved with aggressive surgical resection and immunotherapy.

AB - BACKGROUND. The management of renal cell carcinoma (RCC) is evolving toward less extirpative surgery and the use of targeted therapy. The authors set out to provide a benchmark against which emerging therapies should be measured. METHODS. A prospective database including clinical and pathological variables for 1632 patients with RCC treated between 1989 and 2005 was queried. Patients were stratified using the University of California-Los Angeles Integrated Staging System (UISS) into low-, intermediate-, and high-risk groups. Disease-specific survival (DSS) was measured. Response to systemic therapy for patients with advanced disease was assessed. RESULTS. Nephrectomy was performed in 1492 patients. Overall 5-, 10-, and 15-year DSS was 55%, 40%, and 29%. For localized disease, 5- and 10-year DSS for UISS low-, intermediate-, and high-risk groups was 97% and 92%, 81% and 61%, and 62% and 41%, respectively. For metastatic disease, 5- and 10-year DSS for UISS low-, intermediate-, and high-risk groups was 41% and 31%, 18% and 7%, and 8% and 0%, respectively. Patients with metastatic disease receiving immunotherapy (n = 453) had complete response in 7% (median survival [MS], 1201 months), partial response in 15% (MS, 42.8 months), stable disease in 33% (MS, 38.6 months), and progressive disease in 45% (MS, 11.6 months). CONCLUSIONS. Most patients with localized RCC do well with surgery alone, but effective adjuvant therapy is needed for patients identified as at high risk for recurrence. For advanced disease, newer targeted and potentially less toxic treatments should be at least as effective as those achieved with aggressive surgical resection and immunotherapy.

KW - Immunotherapy

KW - Interleukin-2

KW - Kidney cancer

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=55549134997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55549134997&partnerID=8YFLogxK

U2 - 10.1002/cncr.23851

DO - 10.1002/cncr.23851

M3 - Article

C2 - 18823034

AN - SCOPUS:55549134997

VL - 113

SP - 2457

EP - 2463

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 9

ER -